Tessera Defense & Homeland Security Inc. (HLSQ) amended its Share Purchase and Option Agreement with Mayers Ventures LLC to increase its planned initial stake in M.E.A. Testing Systems Ltd. from 10% to 15% of MEA’s share capital on a fully diluted basis, subject to listing approval.
The consideration now includes 195,000 Tessera common shares (130,000 issued at closing and 65,000 issuable upon NYSE American authorization), which equals about 4.5% of Tessera’s outstanding common stock. Tessera also established an unsecured up to $475,000 convertible loan to the seller at 12% interest, convertible into MEA shares based on MEA’s 2027 EBITDA or a $10,000,000 valuation, capped at 19.999% total MEA ownership.
Separately, MEA granted Tessera a perpetual, irrevocable, worldwide, fully paid-up and royalty-free license, exclusive for testing, validation and evaluation of unmanned aerial vehicles and propulsion systems and non-exclusive for other defense and security uses. Tessera closed the initial purchase of 324,573 MEA shares (10%) and issued 130,000 Tessera shares on September 16, 2026 under a private placement exemption.
BiomX Inc., now Tessera Defense and Homeland Security Inc. (HLSQ), reports that it has effected a one-for-ten reverse stock split of its common stock and changed its corporate name. The reverse split became effective on September 9, 2026, and the name change on September 11, 2026.
The common stock now trades on NYSE American on a split-adjusted basis under the symbol HLSQ with a new CUSIP, replacing PHGE. Management reports stockholders’ equity attributable to the company of $10.9 million and total equity of $17.6 million as of June 30, 2026, levels described as above NYSE American continued listing standards. Over the prior three months the company raised over $4 million through an at-the-market program at an average split-adjusted price of about $2.20 per share, and the reverse split reduced authorized shares from 750 million to 150 million.
The company highlights that its updated corporate presentation and CEO letter outline a strategy focused on an autonomous physical-security platform for homeland security and critical infrastructure, built around subsidiaries Zorronet and DFSL and a minority stake in Motomea. Forward-looking statements acknowledge risks including a history of losses, substantial doubt about its ability to continue as a going concern, and the challenge of regaining and maintaining compliance with NYSE American listing standards within the plan period ending September 25, 2027.
BiomX Inc. (HLSQ), now operating as Tessera Defense & Homeland Security Inc., is the subject of an amended Schedule 13D in which Water IO Ltd., Star 26 Capital Inc., T3 Defense Inc. and Menachem Shalom report their updated holdings. After a one-for-ten reverse stock split effective September 9, 2026, the group holds 156,796 shares of common stock, or 3.87% of the class. This reflects 130,000 shares previously acquired under a securities purchase agreement and 26,796 shares issued on September 15, 2026 as partial interest and consideration under a promissory note amendment. As of September 15, 2026, the reporting persons state they are no longer beneficial owners of more than 5% of the company’s common stock, and this amendment is described as their final, “exit” filing.
BiomX Inc. (PHGE) is implementing a capital and branding change that includes a reverse stock split and a corporate name change. A Certificate of Amendment effective at 12:01 a.m. Eastern Time on September 9, 2026 effects a one-for-ten reverse stock split of the company’s common stock and reduces authorized common shares from 750,000,000 to 150,000,000. Trading in the common stock on the NYSE American will begin on a split-adjusted basis on September 9, 2026 under CUSIP 09090D 608, with fractional shares rounded up to the nearest whole share at the record holder and DTC participant level. A separate amendment will become effective at 12:01 a.m. Eastern Time on September 11, 2026, changing the company’s name from BiomX Inc. to Tessera Defense and Homeland Security Inc., after which the stock will trade under the new ticker symbol HLSQ on the NYSE American while retaining the same CUSIP number.
BiomX Inc. (PHGE) reported that it will change its corporate name to Tessera Defense and Homeland Security Inc., effective at 12:01 a.m. ET on September 11, 2026, following approval by its Board of Directors. Under Delaware law, no stockholder approval is required, and the company plans to file a certificate of amendment to its charter to implement the change.
On September 11, 2026, the common stock will begin trading on the NYSE American under the new ticker symbol HLSQ, and will trade under PHGE until then. The shares will be identified by CUSIP 09090D 608, which is being assigned in connection with a previously announced one-for-ten reverse stock split expected to become effective on September 9, 2026 and will not change as a result of the name change. The company states that the name change and reverse stock split are separate corporate actions, do not affect stockholder rights, and require no action or certificate exchange by stockholders.
BiomX Inc. (PHGE) is implementing a one-for-ten reverse stock split of its common stock. The Board fixed the split ratio at 1-for-10 and expects it to become effective at 12:01 a.m. Eastern Time on September 9, 2026, after filing a Certificate of Amendment in Delaware that also reduces authorized common shares from 750,000,000 to 150,000,000.
Each block of ten pre-split shares will be combined into one post-split share, reducing outstanding common stock from approximately 27.3 million shares as of August 31, 2026 to approximately 2.7 million, without changing par value. Holders of record who would otherwise receive fractional shares will receive one whole share instead, while fractional interests for beneficial owners in street name will be handled under nominee procedures. Proportionate adjustments will apply to outstanding warrants, convertible instruments and equity awards, and the reverse split is expected to affect all stockholders uniformly aside from minor changes from fractional share treatment.
BiomX Inc. (PHGE) announced a 1-for-10 reverse stock split of its common stock. The Board set the ratio on August 28, 2026, after prior stockholder approval of a reverse split in the range of 1-for-5 to 1-for-20, together with a reduction in authorized shares.
The reverse split and related Certificate of Amendment are expected to become effective at 12:01 a.m. ET on September 9, 2026, with trading on the NYSE American beginning on a split-adjusted basis that day. Each 10 pre-split shares will be combined into 1 post-split share, reducing outstanding shares from approximately 26.7 million to approximately 2.7 million, while authorized common shares will decrease from 750,000,000 to 150,000,000. Fractional shares will be rounded up to the next whole share, and percentage ownership will remain essentially unchanged aside from rounding effects.
BiomX Inc. (PHGE) reported results of a Special Meeting of Stockholders held on August 25, 2026. As of the August 10, 2026 record date, 26,559,607 shares of common stock were outstanding and entitled to vote, with 9,813,430 shares present, representing 36.9% of eligible shares and constituting a quorum.
Stockholders approved the issuance of common stock and related securities to Mandragola Ltd. in connection with acquiring controlling equity interests in Dr. Frucht Systems Ltd., including securities linked to a Line of Credit and a potential Revenue Bonus. They also approved a reverse stock split authorization at a ratio between 1-for-5 and 1-for-20, to be implemented at the Board’s discretion before the first anniversary of the Special Meeting; if implemented, authorized common shares would decrease from 750,000,000 to 150,000,000. Stockholders ratified Barzily & Co. as independent registered public accounting firm for the fiscal year ending December 31, 2026 and approved an adjournment proposal, though no adjournment was needed.
BiomX Inc. (PHGE) is the subject of this Amendment No. 5 to a Schedule 13G/A filed by the Cystic Fibrosis Foundation. The foundation reports beneficial ownership of 174,276 shares of BiomX common stock, representing 1.47% of the class, with sole voting and dispositive power over all reported shares. The filing indicates that the Cystic Fibrosis Foundation now owns 5 percent or less of BiomX’s common stock.
BiomX Inc. (PHGE) reports a major strategic and financial transformation for the quarter ended June 30, 2026, shifting from phage-based drug development to defense, security and critical infrastructure technology. It completed business acquisitions of ZorroNet and a 60% stake in DFSL, adding $25.4 million of goodwill and other intangibles and creating $6.8 million of non‑controlling interests. Total assets rose to $28.2 million from $5.8 million at December 31, 2025, and stockholders’ equity moved from a deficit of $(1.3) million to positive equity of $17.6 million, driven largely by these transactions and warrant-related equity issuances.
Operations remain highly loss‑making and cash‑constrained. Revenue for the first half of 2026 was $0.3 million, while net loss was $23.0 million, including large non‑cash charges from warrant and derivative remeasurement and a $5.2 million day‑one loss on a financing transaction, partly offset by a $1.9 million gain from deconsolidating insolvent BiomX Israel. Operating cash outflow was $6.6 million and period‑end cash and cash equivalents were only $0.3 million. Management explicitly states there is substantial doubt about the company’s ability to continue as a going concern absent additional financing, and plans to rely on equity/debt raises, an at‑the‑market program, and new revenue from DFSL and ZorroNet.